Fine Foods & Pharmaceuticals N.T.M. SpA (IT:FF)
:FF
Want to see IT:FF full AI Analyst Report?
FF Stock Chart & Stats
€9.40
€0.00(0.00%)
At close: 4:00 PM EST
€9.40
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€7.48 - €11.90
Previous CloseN/A
Volume1.45K
Average Volume (3M)32.76K
Market Cap
€218.52M
Enterprise Value€279.63M
Total Cash (Recent Filing)€24.94M
Total Debt (Recent Filing)€85.94M
Price to Earnings (P/E)28.7
Beta0.41
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.48%
Share Statistics
EPS (TTM)0.26
Shares Outstanding22,060,125
10 Day Avg. Volume35,964
30 Day Avg. Volume32,755
Financial Highlights & Ratios
PEG Ratio0.97
Price to Book (P/B)1.82
Price to Sales (P/S)0.97
P/FCF Ratio-85.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.43Price Target Upside42.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.59
Revenue Forecast (FY)€268.64M
Bulls Say, Bears Say
Bulls Say
Contract Manufacturing Business ModelFF's core CMO/CDMO model targets nutraceutical and pharmaceutical clients, creating repeatable, specification-driven revenue. Regulatory compliance and formulation capabilities create switching costs and long sales cycles, supporting predictable multi-month contracts and durable revenue streams.
Recovered, Stable ProfitabilityReturn to mid-single-digit operating margins and a positive net margin indicates the business has re-established operational discipline and pricing power. Sustained margins improve cash generation potential and provide a buffer against cyclical demand swings over the medium term.
Moderate Leverage And Equity BaseDebt-to-equity of ~0.65 (improved from ~0.90) indicates a more conservative capital structure and sizable equity relative to assets. This reduces insolvency risk, preserves borrowing capacity for capex or working-capital needs, and supports long-term operational continuity.
Bears Say
Negative Free Cash FlowPersistent negative FCF despite solid operating cash generation indicates high reinvestment, capex, or working-capital absorption. This reduces financial flexibility for debt reduction or shareholder returns and may force external funding if the pattern continues over multiple quarters.
Choppy Revenue MomentumIrregular revenue: strong 2023, decline 2024, modest 2025 growth and slight TTM decline undermines predictability. Lack of steady top-line expansion limits scale benefits, complicates long-term planning, and weakens prospects for sustainably improving margins and returns.
Volatile Gross Profit ProfileLarge year-to-year swings in gross profit point to exposure to input-cost volatility, pricing mix shifts, or accounting comparability issues. Such variability makes margin forecasting unreliable and increases execution risk for maintaining profitability under adverse cost or demand conditions.
Fine Foods & Pharmaceuticals N.T.M. SpA News
FF FAQ
What was Fine Foods & Pharmaceuticals N.T.M. SpA’s price range in the past 12 months?
Fine Foods & Pharmaceuticals N.T.M. SpA lowest stock price was €7.48 and its highest was €11.90 in the past 12 months.
What is Fine Foods & Pharmaceuticals N.T.M. SpA’s market cap?
Fine Foods & Pharmaceuticals N.T.M. SpA’s market cap is €218.52M.
When is Fine Foods & Pharmaceuticals N.T.M. SpA’s upcoming earnings report date?
Fine Foods & Pharmaceuticals N.T.M. SpA’s upcoming earnings report date is Sep 08, 2026 which is in 86 days.
How were Fine Foods & Pharmaceuticals N.T.M. SpA’s earnings last quarter?
Fine Foods & Pharmaceuticals N.T.M. SpA released its earnings results on May 07, 2026. The company reported €0.036 earnings per share for the quarter, beating the consensus estimate of N/A by €0.036.
Is Fine Foods & Pharmaceuticals N.T.M. SpA overvalued?
According to Wall Street analysts Fine Foods & Pharmaceuticals N.T.M. SpA’s price is currently Undervalued.
Does Fine Foods & Pharmaceuticals N.T.M. SpA pay dividends?
Fine Foods & Pharmaceuticals N.T.M. SpA pays a Annually dividend of €0.16 which represents an annual dividend yield of 1.48%. See more information on Fine Foods & Pharmaceuticals N.T.M. SpA dividends here
What is Fine Foods & Pharmaceuticals N.T.M. SpA’s EPS estimate?
Fine Foods & Pharmaceuticals N.T.M. SpA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fine Foods & Pharmaceuticals N.T.M. SpA have?
Fine Foods & Pharmaceuticals N.T.M. SpA has 22,060,125 shares outstanding.
What happened to Fine Foods & Pharmaceuticals N.T.M. SpA’s price movement after its last earnings report?
Fine Foods & Pharmaceuticals N.T.M. SpA reported an EPS of €0.036 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -9.149%.
Which hedge fund is a major shareholder of Fine Foods & Pharmaceuticals N.T.M. SpA?
Currently, no hedge funds are holding shares in IT:FF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fine Foods & Pharmaceuticals N.T.M. SpA
Fine Foods & Pharmaceuticals N.T.M. S.p.A. functions as a contract development and manufacturing organization (CDMO), specializing in the creation of various oral solid forms for the pharmaceutical and nutraceutical sectors. Its pharmaceutical offerings include items such as powders, granules, capsules, standard and film-coated tablets, effervescent granules, and hard gelatine capsules. For the nutraceutical market, the company produces soluble, effervescent, and chewable tablets, fast-melting/sublingual tablets, film-coated tablets, and hard gelatine capsules, alongside soluble and effervescent powders and granules. These nutraceutical products are designed to support a wide range of health needs, encompassing areas like probiotics, multivitamins and minerals, immune system function, sleep and relaxation, gastrointestinal and circulatory health, osteoarticular and urinary systems, women's health, beauty, healthy aging, and mental wellbeing. In addition to its core CDMO services, the company also manufactures and sells a diverse array of cosmetic products, covering hair care, skin care, liquid personal hygiene items, oral hygiene products, deodorants, alcohol-based perfumery, bath and shower gels, shampoos and conditioners, shaping waxes, mouthwashes, creams, gels, and toothpastes. Furthermore, they supply medical surgical aids and devices, various antiseptics for intact skin, hand sanitizers, pre-injection solutions, hydroalcoholic surface cleaners, and iodine. Their product line also extends to orthodontic cleaning tablets, disinfectants, and decongestant nasal sprays. Established in 1984, the company is headquartered in Verdellino, Italy.
FF Stock 12 Month Forecast
Average Price Target
€13.43
▲(42.91% Upside)
Technical Analysis
Valsoia SpA
―
Enervit S.p.A.
―
High Quality Food SpA
―
Italian Wine Brands S.p.A.
―
NewPrinces S.p.A.
―
Options Prices
Currently, No data available
---